{"id":"rezafungin-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rezafungin binds to and inhibits the fungal enzyme 1,3-beta-D-glucan synthase, which is essential for the synthesis of beta-glucan, a critical structural component of the fungal cell wall. This disruption of cell wall integrity leads to fungal cell lysis and death. As an echinocandin, it has broad-spectrum activity against Candida and Aspergillus species with a long half-life suitable for intravenous administration.","oneSentence":"Rezafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis by targeting 1,3-beta-D-glucan synthase.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:58.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive candidiasis"},{"name":"Candidemia"}]},"trialDetails":[{"nctId":"NCT04368559","phase":"PHASE3","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mundipharma Research Limited","startDate":"2020-05-11","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":602},{"nctId":"NCT06794554","phase":"PHASE2","title":"Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options","status":"RECRUITING","sponsor":"Mundipharma Research Limited","startDate":"2025-06-30","conditions":"Chronic Pulmonary Aspergillosis","enrollment":60},{"nctId":"NCT03667690","phase":"PHASE3","title":"Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2018-10-07","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":199},{"nctId":"NCT04117607","phase":"PHASE1","title":"Safety and Pharmacokinetics of Rezafungin","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-04","conditions":"Fungal Infection","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intravenous antifungal therapy"],"phase":"phase_3","status":"active","brandName":"Rezafungin for Injection","genericName":"Rezafungin for Injection","companyName":"Mundipharma Research Limited","companyId":"mundipharma-research-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rezafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis by targeting 1,3-beta-D-glucan synthase. Used for Invasive candidiasis, Candidemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}